Yes you could be correct but it says "up to 6 months"
Also, I wouldn't be surprised of updates on the way:
The study is designed as a dose escalation study. Dosing will commence with the lowest dose cohort (0.03 mg/kg ARG007/placebo). Once at least 6 subjects in a given dose cohort completed dosing, safety data will be reviewed by a SRC prior to dose escalation to the next dose cohort. The study will consist of a screening period, treatment period and follow-up period.
Ann: Phase 1 Clinical Trial Summary, page-4
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
84.0¢ |
Change
0.055(7.01%) |
Mkt cap ! $106.7M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 87.0¢ | 81.5¢ | $93.54K | 111.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14959 | 83.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 84.0¢ | 1190 | 1 |
View Market Depth
| Last trade - 11.01am 06/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |